Imagine a simple tablet that balances the natural environment of the vagina to fight off bad bacteria and fungi without using harsh antibiotics. It works like a reset button for the body's natural defenses, meaning women don't need a lab test to know which infection they have before treating it. This helps avoid the growing problem of drug-resistant germs while keeping the natural microbiome healthy.
Women suffer from BV and VVC causing high healthcare costs and preterm births, yet current treatments rely on antibiotics that fuel antimicrobial resistance. There is a lack of accessible, non-antibiotic OTC options that treat both conditions without requiring a prior lab diagnosis.
A patented, antimicrobial-free vaginal tablet (pessary) and the associated clinical trial data proving its efficacy in treating bacterial vaginosis.
If you are a drug manufacturer dealing with the rise of antimicrobial resistance — this project developed a patented, antimicrobial-free tablet that treats both BV and VVC. This allows for a first-line OTC solution that doesn't require pathogen identification. It targets a market with over 500 million cases per year.
If you are a pharmacy chain dealing with the fact that 90% of women seek treatment for vaginal infections in-store — this project developed a safe, CE-marked tablet. It provides a high-demand product for the OTC market that reduces the need for prescription antibiotics. This addresses a healthcare cost burden exceeding €3.8 billion in Europe.
If you are a distributor dealing with the need for scalable women's health products — this project developed a B2B2C model for a vaginal pessary. The product is designed for rapid commercial deployment across Europe and beyond. It targets a massive unmet need affecting millions of women globally.
Based on available project data, specific unit pricing is not disclosed, but the product is positioned as an over-the-counter (OTC) solution for pharmacies and drugstores.
Gedea uses a B2B2C business model, scaling through planned partnerships with distributors and pharmaceutical companies to accelerate deployment across Europe and other regions.
The pHyph formula is patented. The company intends to commercialize it via a scalable model involving partnerships with pharma companies.
The project is working toward obtaining CE-mark certification and completing clinical trials to ensure a safe profile for OTC sale.
The project aims for a full market launch in 2026.
The project is led by a single SME, GEDEA BIOTECH AB from Sweden. The consortium is 100% industry-driven, indicating a strong focus on commercialization rather than academic research. The core team is lean (9 persons) but highly experienced, boasting over 250 combined years of expertise in clinical research, regulatory affairs, and business development.
Contact GEDEA BIOTECH AB in Sweden
Contact us to explore licensing or distribution partnerships for pHyph.
